Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 17,610 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the completion of the sale, the chief executive officer owned 615,802 shares in the company, valued at $372,627,948.22. This represents a 2.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Medpace Stock Down 1.4%
NASDAQ:MEDP traded down $8.52 on Wednesday, hitting $596.98. The stock had a trading volume of 310,338 shares, compared to its average volume of 355,204. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The business’s 50-day simple moving average is $528.36 and its two-hundred day simple moving average is $491.85. The stock has a market cap of $16.66 billion, a price-to-earnings ratio of 34.99, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Report on Medpace
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in Medpace during the 2nd quarter valued at approximately $687,000. Evolve Private Wealth LLC purchased a new position in shares of Medpace in the second quarter worth $1,386,000. Westpac Banking Corp purchased a new position in shares of Medpace in the second quarter worth $437,000. Ieq Capital LLC bought a new position in shares of Medpace during the second quarter worth $20,323,000. Finally, Heron Bay Capital Management bought a new position in shares of Medpace during the second quarter worth $16,038,000. 77.98% of the stock is owned by hedge funds and other institutional investors.
Medpace Company Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Featured Articles
- Five stocks we like better than Medpace
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
